Let’s crunch

Log In | Sign Up



DexCom

Selected Articles

2025-08-13
GlobeNewswire
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk
2025-08-13
GlobeNewswire
Smart Medical Devices Market to Grow at 17.1% CAGR Through 2030
2025-08-11
GlobeNewswire
Tandem Diabetes Care Inc. (TNDM) - Product Pipeline Analysis Report 2025
2025-08-10
ETF Daily News
Wall Street Zen Downgrades DexCom (NASDAQ:DXCM) to Buy
2025-08-08
Medtechdive.com
Tandem, Insulet monitoring CMS payment proposal for diabetes tech
2025-08-07
Yahoo Entertainment
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock
2025-08-07
GlobeNewswire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
2025-08-05
Yahoo Entertainment
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change
2025-08-04
ETF Daily News
Leerink Partnrs Predicts DexCom's Q3 Earnings (NASDAQ:DXCM)
2025-08-03
ETF Daily News
DexCom (NASDAQ:DXCM) Upgraded by William Blair to Strong-Buy Rating

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. US2521311074 www.dexcom.com